Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Trial Profile

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 17 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Apr 2017 Status changed from suspended to recruiting.
    • 15 Mar 2017 Treatment arms has been increases from 5 to 6. hence patient number also increases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top